Wegovy maker Novo Nordisk's sales hike in second quarter
Wegovy maker Novo Nordisk's sales hike in second quarter
Wegovy maker Novo Nordisk sales rise 18% in second quarter
Wegovy-maker Novo Nordisk reported second-quarter sales up 18% on Wednesday, below initial analyst expectations, after a major profit warning and new CEO announcement last week wiped some $95 billi...
Novo Nordisk's sales increased by 16% in Danish kroner and by 18% at constant exchange rates to DKK 154.9 billion in the first six months of 2025
Bagsværd, Denmark, 6 August 2025 - Financial report for the period 1 January 2025 to 30 June 2025
Novo Nordisk's weight loss challenge in five charts
Danish drugmaker Novo Nordisk is facing a major challenge to its blockbuster weight-loss drug Wegovy.
Investor Alert: Robbins LLP Informs Investors of the Novo Nordisk A/S Class Action Lawsuit
SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Novo Nordisk A/S (NYSE: NVO) s...
Novo Nordisk A/S Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 30, 2025 to Discuss Your Rights – NVO
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Novo Nordisk A/S ("Novo" or the "Company") (NYSE: NVO) of a class action securities lawsuit.
Berger Montague PC Announces Class Action Filed Against Novo Nordisk A/S (NYSE: NVO) for Alleged Securities Violations
PHILADELPHIA , Aug. 5, 2025 /PRNewswire/ -- Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global ph...
Novo Nordisk expands lawsuits against weight-loss drug compounders
Danish drugmaker Novo Nordisk said on Tuesday it has filed 14 new lawsuits in the United States against the sale of unapproved versions of semaglutide, the main ingredient in its popular weight-los...
Nordisk to downgraded by leading investment bank as growth slows and competition intensifies
UBS has lowered its rating on Novo Nordisk (NYSE:NVO) from 'buy' to 'neutral', slashing the price target to DKK340 from DKK600. The downgrade comes after what UBS described as “challenging times” f...
NOVO NORDISK A/S (NYSE: NVO) INVESTOR ALERT – Investors With Large Losses in Novo Nordisk A/S Should Contact Bernstein Liebhard LLP To Discuss Thei...
NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acq...
Berger Montague PC Investigating Claims on Behalf of Novo Nordisk A/S (NYSE: NVO) After Class Action Filing
PHILADELPHIA, Aug. 04, 2025 (GLOBE NEWSWIRE) -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Novo Nordisk A/S (NYSE: NVO) (“Novo” or the “Company”) on b...
Watch These Novo Nordisk Stock Price Levels After Last Week's 33% Drop
Novo Nordisk's (NVO) U.S.-listed shares were up about 2% in recent trading after shedding about a third of their value last week, when the company cut its full-year outlook and named a new CEO, lea...
NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $NVO--NVO Investors Have Opportunity to Lead Novo Nordisk A/S Securities Fraud Lawsuit with the Schall Law Firm.
Faruqi & Faruqi Reminds Novo Nordisk Investors of The Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Novo To Contact Him Directly To Discuss Their Options If you su...
Novo Nordisk: I Was Wrong Twice, But This Selloff Looks Like 2016 All Over Again
I'm downgrading Novo Nordisk from Strong Buy to Buy due to recent guidance cuts, competitive pressures, and persistent compounded GLP-1 drug erosion. The long-term obesity drug opportunity, Novo's ...
Related Companies